Prelude Therapeutics (PRLD) AI Stock Analysis

• Market Cap: $50.04M
• Dividend Yield: N/A
• Average Volume (3M): 114.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: N/A
• EPS Growth: 16.38%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.42
• Shares Outstanding: 43,610,220
• 10 Day Avg. Volume: 122,755
• 30 Day Avg. Volume: 114,354
• PEG Ratio: -0.08
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3.33
• Price Target Upside: 274.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 35 Underperform
• Price Target: ―

Prelude Therapeutics faces significant financial hurdles due to ongoing losses and lack of revenue, which heavily impact its overall score. Technical analysis shows mixed short-term momentum, but long-term weakness persists. The valuation is challenged by a negative P/E ratio and lack of dividends. However, recent corporate developments, including promising clinical results and a solid cash runway, offer some positive aspects, albeit insufficient to offset the broader financial concerns.

Positive Factors

Analyst Recommendation

Analyst reiterates a Buy rating and sets a 12-month price target of $5 for Prelude Therapeutics.

Clinical Trials

Presentation of updated results from the Phase 1 trial evaluating PRT3789 in biomarker-selected SMARCA4-mutated cancers is expected to be a catalyst.

Financial Position

Prelude Therapeutics has a first-mover advantage in the SMARCA2-targeted degrader space.

Negative Factors

Clinical Risks

Risks include negative clinical results for PRT3789 and delays in advancing these candidates into registrational programs.

Market Competition

The competitive landscape poses risks, particularly with respect to other SMARCA2 inhibitors/degraders that are currently in clinical development.

Treatment Discontinuation

Treatment discontinuations due to treatment emergent adverse events occurred in five patients in the monotherapy cohort.

Prelude Therapeutics Business Overview & Revenue Model

Company Description

Prelude Therapeutics (PRLD) is a biopharmaceutical company dedicated to the discovery and development of innovative cancer therapies. The company focuses on creating small-molecule therapies that target key drivers of cancer cell growth, survival, and resistance. Prelude Therapeutics operates within the biotechnology and pharmaceutical sectors, aiming to address unmet medical needs in oncology through its research and development efforts.

How the Company Makes Money

Prelude Therapeutics primarily makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model includes out-licensing its drug candidates to larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on sales if the drugs are successfully developed and commercialized. Prelude may also engage in collaborative research and development partnerships with other biotech or pharmaceutical companies, which can provide additional funding and resources. Additionally, the company might receive grants or funding from government or non-profit organizations to support its research efforts. As a clinical-stage company, Prelude's revenue may be limited until its drug candidates receive regulatory approval and reach the market.

Prelude Therapeutics Financial Statement Overview

Summary

Prelude Therapeutics is facing severe financial challenges with no revenue generation and increasing losses. The balance sheet remains moderately leveraged, but declining equity and increasing liabilities are concerning. Persistent negative cash flow from operations exacerbates the financial strain, underscoring the need for strategic adjustments to enhance financial stability.

Income Statement

Prelude Therapeutics has consistently reported zero revenue over the past years, indicating no sales generation. The company is incurring substantial EBIT and net losses, which are increasing annually, reflecting mounting operational challenges. The lack of any revenue growth and negative profit margins highlight significant financial strain.

Balance Sheet

The balance sheet shows a relatively stable equity position, though declining over the years. The debt-to-equity ratio remains low, which indicates limited leverage use. However, the continuous decline in stockholders' equity coupled with increasing liabilities suggests growing financial pressure.

Cash Flow

Cash flow from operations remains negative and has worsened, which indicates ongoing cash burn. Although free cash flow shows a negative trajectory, the company has managed to access financing, which temporarily boosts liquidity. The lack of revenue significantly hampers cash generation capabilities.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.00M	0.00	0.00	0.00	0.00
	Gross Profit
7.00M	-1.17M	-3.04M	-2.24M	-542.00K
	EBIT
-139.71M	-132.28M	-123.54M	-113.73M	-58.76M
	EBITDA
-139.71M	-131.11M	-122.22M	-112.82M	-58.22M
	Net Income Common Stockholders
-127.17M	-121.83M	-107.34M	-110.78M	-56.93M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
133.61M	232.94M	201.73M	291.23M	218.31M
	Total Assets
175.51M	277.67M	220.50M	305.10M	223.59M
	Total Debt
18.02M	16.89M	1.83M	1.74M	0.00
	Net Debt
5.55M	-8.40M	-28.77M	-30.09M	-218.31M
	Total Liabilities
44.06M	40.58M	25.06M	19.20M	11.41M
	Stockholders Equity
131.46M	237.09M	195.44M	285.90M	212.18M
Cash Flow		Free Cash Flow
-103.65M	-110.58M	-86.75M	-85.85M	-46.80M
	Operating Cash Flow
-102.89M	-107.06M	-83.73M	-83.53M	-46.18M
	Investing Cash Flow
90.19M	-34.65M	81.69M	-263.80M	-621.00K
	Financing Cash Flow
-120.00K	136.40M	815.00K	164.90M	246.23M

Prelude Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.89
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRLD, the sentiment is Neutral. The current price of 0.89 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.80, and below the 200-day MA of 1.69, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 51.74 is Neutral, neither overbought nor oversold. The STOCH value of 32.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRLD.

Prelude Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	53 Neutral	$56.62M	―	-71.64%	―	-98.90%	-177.17%
Sector *	53 Neutral	$5.14B	3.23	-45.01%	2.85%	17.55%	-0.69%
SPRO	48 Neutral	$38.93M	10.83	-107.28%	―	-71.68%	-397.61%
CELU	45 Neutral	$54.84M	―	-232.51%	―	138.11%	76.60%
ITRM	35 Underperform	$37.27M	―	607.06%	―	―	55.67%
PRLD	35 Underperform	$50.04M	―	-81.44%	―	―	16.38%
ANTX	34 Underperform	$35.31M	―	-49.32%	―	―	38.98%

Prelude Therapeutics Corporate Events

Prelude Therapeutics Reports 2024 Financial Results and Updates

Prelude Therapeutics reported its financial results for 2024 and provided updates on its clinical development pipeline. The company highlighted the progress of its SMARCA2 degrader programs, including PRT3789, which has shown promising results in treating SMARCA4-deficient cancers. Prelude’s financial position remains strong, with a cash runway extending into the second quarter of 2026. The company continues to focus on advancing its precision oncology medicines and expects to share further data in 2025.

Prelude Therapeutics Appoints Bryant D. Lim as CFO

Prelude Therapeutics has appointed Bryant D. Lim as the permanent Chief Financial Officer, effective February 3, 2025, while he continues his roles as Chief Legal Officer and Corporate Secretary. This decision follows his interim CFO position, and his employment agreement includes a base salary, bonus eligibility, stock options, and benefits contingent upon his continued service and compliance with the agreement.